[18F] Fluorocholine FCH Positron Emission Tomography (PET)/Computed Tomography (CT) for Detection of Prostate Cancer Lymph Nodes Metastases (PROPET)
Recruitment status was: Recruiting
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Diagnostic
|Official Title:||Evaluation of [18F] Fluorocholine PET/CT for Detection of Regional Lymph Node Metastases From Prostate Cancer|
- The primary target variable "metastasizes to regional lymph nodes" (yes/no) will be used to estimate the diagnostic usefulness of FCH PET/CT in terms of sensitivity, specificity, positive and negative predictive values. [ Time Frame: The [18F] Fluorocholin PET/CT and the lymphadenectomi is done within 1 month ]
|Study Start Date:||January 2008|
|Estimated Study Completion Date:||April 2013|
|Estimated Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
Procedure: [18F] Fluorocholine PET/CT
The patients fast 6 hours before the [18F]Fluorocholine PET/CT scan. [18F]Fluorocholine will be used as tracer with a dosage of 4 MBq per kg bodyweight. PET/CT imaging will be performed after 15 and 60 after the intravenous injection of the tracer. The patient will receive 2 full body FCH PET/CT. The CT scan is with contrast.
The radiation exposure from the CT scan is 9 mSv and from the PET scan it is 3 mSv, giving a total of 12 mSv, which equals 4 times the yearly background radiation in Denmark.
The purpose of this prospective trail is to improve the staging of patients with prostate cancer. The investigators focus on the group of patients with a newly diagnosed prostate cancer, and specifically the ones who have an intermediate and high risk of disseminated prostate cancer.
The aim is to improve staging by replacing the traditional invasive method, the lymphadenectomy, which has a rather low sensitivity by a non-invasive method, 18F-choline PET/CT which has a presumably superior sensitivity.
The treatment of patients with prostate cancer relies on the stage of the disease. Patients with disseminated prostate cancer are incurable and are treated with palliatively. In contrast, patients with localized prostate cancer are offered curative therapy. Hence, the stage of prostate cancer is crucial for the choice of treatment.
The potential benefits are
- The patients avoid the surgical trauma including complications and convalescents period.
- The accuracy of the prostate cancer staging is improved, the potential of which is better survival.
The patients are 18F-choline PET/CT scanned prior to their lymphadenectomy, the results of the 18F-choline PET/CT are blinded for the surgeon. The endpoint of the trail is the comparison of 18F-choline PET/CT and the histopathological investigation of the regional lymph nodes of prostate.
Assuming a prevalence of metastasised prostate cancer of 20% and a true (unknown) sensitivity of FCH PET/CT of 95%, 205 patients are sufficient to show that the sensitivity of the FCH PET/CT is greater than 80% with a power of 80% at significance level 5%. The size of the confidence interval for specificity of FCH PET/CT is expected to become reasonable small. In opposition to lymphadenectomy, FCH PET/CT results may point to metastases in neighbouring regions which gives an additional benefit to FCH PET/CT justifying a test level for sensitivity of 80%."
Accordingly 205 patients will be included over 2½ years. The first patients have been included in January 2008. Interim analyses will be done after 25, 50 and 100 patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00670527
|Contact: Mads Hvid Poulsen, MD||Mads.Poulsen@ouh.regionsyddanmark.dk|
|Contact: Steen Walter, MD, DMSci, Professor|
|Department of Urology, Odense University Hospital||Recruiting|
|Odense, Denmark, 5000|
|Contact: Mads Hvid Poulsen, MD Mads.Poulsen@ouh.regionsyddanmark.dk|
|Contact: Steen Walter|
|Principal Investigator:||Mads Hvid Poulsen, MD||Department of Urology, Odense University Hospital, Denmark|
|Study Chair:||Ulla Geertsen, MD, Head of Department||Department of Urology, Odense University Hospital, Denmark|
|Study Chair:||Niels Svolgaard, MD, Senior Physician||Department of Urology, Odense University Hospital, Denmark|
|Study Chair:||Steen Walter, MD, DMSci, Professor||Department of Urology, Odense University Hospital, Denmark|
|Study Chair:||Kirsten Bouchelouche, MD, DMSci||Odense University Hospital|
|Study Chair:||Mette Høilund-Carlsen, Head Technician||Odense University Hospital|
|Study Chair:||Henrik Petersen, MD, Senior Physician||Odense University Hospital|
|Study Chair:||Mattias Ögren, Radiochemist, PhD||Odense University Hospital|
|Study Chair:||Poul F Høilund-Carlsen, MD, DMSci, Professor||Department of Nuclear Medicine, Odense University Hospital, Demnark|
|Study Chair:||Oke Gerke, Post-Doc, PhD||University of Southern Denmark|
|Study Chair:||Werner Vach, PhD, Professor||University of Southern Denmark|
|Study Chair:||Birgitte Svolgaard, MD, Senior Physician||Odense University Hospital|
|Study Chair:||Niels Marcussen, MD, DMSci, Professor||Odense University Hospital|